

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

John Ieni

Art Unit: 4121

Application No: 10/591,608

Examiner: J. P. Cornet

Confirmation No: 3117

Filed: December 26, 2007

Atty. Docket No: 61368-233549

For: CADASIL TREATMENT WITH
CHOLINESTERASE INHIBITORS

Customer No:

26694

PATENT TRADEMARK OFFICE

ELECTION

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam:

In response to the restriction requirement set forth in the Office Action mailed March 30, 2009, Applicant hereby elects Group I, claims 1-10. In response to the requirement that species be elected, Applicant elects donepezil (the compound of formula IV in claim 1 and/or its hydrochloride; formula IVa in claim 2) as a cholinesterase inhibitor; and atorvastatin as a HMG-CoA reductase inhibitor, for examination.


Applicant understands that upon allowance of a generic claim, Applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim.

Early and favorable consideration of the application is respectfully requested. Please charge any required fees or credit any refunds to Deposit Account No. 22-0261.

Respectfully submitted,

Dated: April 30, 2009

#1027795

By 
Ann S. Hobbs
Registration No.: 36,830
VENABLE LLP
P.O. Box 34385
Washington, DC 20043-9998
(202) 344-4000
(202) 344-8300 (Fax)
Attorney/Agent For Applicant